INFLAMMATORY CYTOKINES DIMINISH NOTCH SIGNALING TO DRIVE REACTIVE EPITHELIAL CHANGES IN EOSINOPHILIC ESOPHAGITIS

in the 4 mg ( p = 0.014), 12 mg ( p = 0.028), and 40 mg ( p = 0.002) groups than in the placebo group.The IBS-SI in 12 mg ( p = 0.048) and 40 mg ( p < 0.001) doses of DSP-6952 groups at the week 4 significantly decreased from the baseline compared with placebo.Diarrhea was observed in 42.9% in the pooled DSP-6952 groups but it was not significantly more than that (37.1%) in the placebo group.No serious AEs were observed in this trial.Conclusion: The results suggest that 40 mg of novel 5-HT 4 agonist DSP-6952 is effective on cardinal features of IBS-C patients without serious AEs.Further development of DSP-6952 for pharmacotherapy in IBS-C is warranted.Clinical trial registration: JapicCTI-122041 Efficacy Endpoints of DSP-6952 a Change from baseline, least square mean (standard error).bPercentage of patients with a score of the global relief of IBS-C symptom assessed with 7-point (1 = completely relieved, 2 = considerably relieved, 3 = slightly relieved, 4 = unchanged, 5 = slightly worsened, 6= considerably worsened, and 7 = worsened most seriously) scale of 3 or lower for all weeks of the treatment period or those with a score of 2 or lower for at least 50% of the treatment period.*p < 0.05 vs placebo.